Minjuvi

<p>Minjuvi is a cancer medicine used first in combination with another medicine called lenalidomide, and then on its own, to treat adults with diffuse large B-cell lymphoma (DLBCL) whose cancer has returned or has stopped responding to other treatments and who cannot have an autologous stem cell transplantation (a transplant where the stem cells are collected from the patients themselves). </p><p>DLBCL is rare, and Minjuvi was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 15 January 2015. Further information on the orphan designation can be found <a href="/en/medicines/human/orphan-designations/eu-3-14-1424" data-entity-type="node" data-entity-uuid="6b487bc3-8e5c-41a4-bac2-cda8ae0bec61" data-entity-substitution="canonical">here</a>.</p><p>Minjuvi contains the active substance tafasitamab.</p>